Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

P2371

Sigma-Aldrich

Pamidronate disodium salt hydrate

≥95% (NMR), solid

Synonym(s):

3-Amino-1-hydroxy-1-phosphonopropanephosphonic acid disodium salt hydrate

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C3H9NO7P2Na2 · xH2O
CAS Number:
57248-88-1
Molecular Weight:
279.03 (anhydrous basis)
EC Number:
260-647-1
MDL number:
MFCD11045314
UNSPSC Code:
12352200
PubChem Substance ID:
24724574
NACRES:
NA.77

Quality Level

100

Assay

≥95% (NMR)

form

solid

color

white

mp

300 °C

solubility

H2O: 28 mg/mL

originator

Novartis

storage temp.

2-8°C

SMILES string

O.[Na+].[Na+].NCCC(O)(P(O)([O-])=O)P(O)([O-])=O

InChI

1S/C3H11NO7P2.2Na.H2O/c4-2-1-3(5,12(6,7)8)13(9,10)11;;;/h5H,1-2,4H2,(H2,6,7,8)(H2,9,10,11);;;1H2/q;2*+1;/p-2

InChI key

TVQNUQCYOOJTMK-UHFFFAOYSA-L

Biochem/physiol Actions

Pamidronate disodium has the ability to block Wnt and β-catenin signaling, which modulates the osteogenic differentiation in bone marrow mesenchymal stem cells (BMMSCs). It can also reduce bilirubin-impaired apoptosis and helps to develop dentinogenic dysfunction of stem cells from human deciduous teeth.
Bone resorption inhibitor; inhibitor of farnesyl diphosphate synthase (IC50 = 200 nM).

Features and Benefits

This compound is a featured product for Cyclic Nucleotide research. Click here to discover more featured Cyclic Nucleotide products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H302

Precautionary Statements

P264 - P270 - P301 + P312 - P501

Hazard Classifications

Acute Tox. 4 Oral

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Yan Wang et al.
PloS one, 7(9), e44868-e44868 (2012-10-03)
It is unclear whether the new anti-catabolic agent denosumab represents a viable alternative to the widely used anti-catabolic agent pamidronate in the treatment of Multiple Myeloma (MM)-induced bone disease. This lack of clarity primarily stems from the lack of sufficient
Evangelos Terpos et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(18), 2347-2357 (2013-05-22)
The aim of the International Myeloma Working Group was to develop practice recommendations for the management of multiple myeloma (MM) -related bone disease. An interdisciplinary panel of clinical experts on MM and myeloma bone disease developed recommendations based on published
Raimund Hirschberg
Current opinion in supportive and palliative care, 6(3), 342-347 (2012-06-20)
More than 10 years ago evidence emerged that bisphosphonate therapy especially in malignant bone diseases is associated with renal complications. The nature of renal injury from bisphosphonates has become clearer in recent years. Pamidronate can rarely cause (collapsing) focal segmental
George Bullock et al.
Materials (Basel, Switzerland), 13(9) (2020-05-07)
Medication-related osteonecrosis of the jaw (MRONJ) is a side effect of bisphosphonate therapy, characterised by exposed necrotic bone. The soft tissues of the oral mucosa no longer provide a protective barrier and MRONJ patients experience pain, infections and difficulties eating.
Ratna Chatterjee et al.
British journal of haematology, 159(4), 462-471 (2012-09-13)
This study aimed to evaluate bone remodelling disorders in thalassaemia by using pamidronate (PD) infusion with or without hormone replacement therapy (HRT) as a diagnostic-therapeutic tool. In this prospective study, 24 adult thalassaemia major (TM) and 10 thalassaemia intermedia (TI)
View All Related Papers

Articles

Discover Bioactive Molecules for Nucleotides

Cyclic nucleotides like cAMP modulate cell function via PKA activation and ion channels.

Discover Bioactive Molecules for Nucleotides

Cyclic nucleotides like cAMP modulate cell function via PKA activation and ion channels.

Discover Bioactive Molecules for Nucleotides

Cyclic nucleotides like cAMP modulate cell function via PKA activation and ion channels.

Discover Bioactive Molecules for Nucleotides

Cyclic nucleotides like cAMP modulate cell function via PKA activation and ion channels.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service